Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Pasqualetti

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Journal of Neuro-Oncology|October 2, 2015
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)Giuseppe Lombardi, Andrea Pace, Francesco Pasqualetti, et al.
The Lancet. Oncology|December 8, 2018
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trialGiuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, et al.
Investigational New Drugs|February 9, 2021
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapyFrancesco Pasqualetti, Alessandra Gonnelli, Paola Orlandi, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2019
[<sup>18</sup>F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancerFrancesco Pasqualetti, Marco Panichi, Martina Sollini, et al.
Neuro-Oncology Advances|June 29, 2026
Prognostic impact of circulating vitamin D and genetic variants in the vitamin D pathway in glioblastomaMariangela Morelli, Francesca Di Lorenzo, Francesca Marchetto, et al.
Genes|June 24, 2022
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-ChemotherapyFrancesco Pasqualetti, Celeste Giampietro, Nicola Montemurro, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 15, 2026
Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma PatientsClaudio Favre, Gianluca Mattei, Cristina Banella, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trialGianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, et al.
Cell Death Discovery|April 13, 2026
BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerabilitySara Franceschi, Mariangela Morelli, Francesca Lessi, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Journal of Neuro-Oncology|October 2, 2015
Predictors of survival and effect of short (40 Gy) or standard-course (60 Gy) irradiation plus concomitant temozolomide in elderly patients with glioblastoma: a multicenter retrospective study of AINO (Italian Association of Neuro-Oncology)Giuseppe Lombardi, Andrea Pace, Francesco Pasqualetti, et al.
The Lancet. Oncology|December 8, 2018
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trialGiuseppe Lombardi, Gian Luca De Salvo, Alba Ariela Brandes, et al.
Investigational New Drugs|February 9, 2021
Association of XRCC3 rs1799794 polymorphism with survival of glioblastoma multiforme patients treated with combined radio-chemotherapyFrancesco Pasqualetti, Alessandra Gonnelli, Paola Orlandi, et al.
Cancers|May 28, 2022
Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter StudyMario Caccese, Matteo Simonelli, Veronica Villani, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 18, 2019
[<sup>18</sup>F]Fluorocholine PET/CT-guided stereotactic body radiotherapy in patients with recurrent oligometastatic prostate cancerFrancesco Pasqualetti, Marco Panichi, Martina Sollini, et al.
Neuro-Oncology Advances|June 29, 2026
Prognostic impact of circulating vitamin D and genetic variants in the vitamin D pathway in glioblastomaMariangela Morelli, Francesca Di Lorenzo, Francesca Marchetto, et al.
Genes|June 24, 2022
Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-ChemotherapyFrancesco Pasqualetti, Celeste Giampietro, Nicola Montemurro, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 15, 2026
Circulating Beta3-Adrenoreceptor as Novel Independent Biomarker for Risk Assessment in Neuroblastoma PatientsClaudio Favre, Gianluca Mattei, Cristina Banella, et al.
European Journal of Cancer (Oxford, England : 1990)|February 12, 2019
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trialGianluca Masi, Caterina Vivaldi, Lorenzo Fornaro, et al.
Cell Death Discovery|April 13, 2026
BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerabilitySara Franceschi, Mariangela Morelli, Francesca Lessi, et al.
Pageof 11